Canada's Spartan Bioscience Launches POC DNA Testing System for PGx Applications
August 12, 2010
Canada's Spartan Bioscience Launches POC DNA Testing System for PGx Applications
The first available test on the system, for the CYP2C19*2 mutation that guides how patients metabolize the anti-coagulant Plavix, is currently in a clinical trial in Canada. The company expects that data from the study will help support regulatory filings around the world for the platform.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Spartan Bioscience Gets CE IVD Mark for 'Sample-to-Answer' CYP2C19 Testing Platform
December 23, 2010 / PCR Insider - Dx Focus: Akonni TruDiagnosis Studies; Spartan Bio CYP2C19 Test; Mitomics Prostate Cancer Assay
January 10, 2013 / PCR Insider - Spartan Bioscience Begins Italian Trial for CYP2C19 DNA Test
December 8, 2011 / PCR Insider - Canadian Trial Validates Spartan Bioscience's Point-of-Care Platform for PGx Applications
November 17, 2011 / PCR Insider - GenomeWeb Feature: Tools for Point-of-Care MDx Available, but Challenges Still Loom
February 28, 2013 / PCR Insider